Verein für
Association pour le
Associazione per il

medizinische Qualitätskontrolle
contrôle de qualité médical
controllo di qualità medico

Survey Report

2023 - 1

MQ, Institut für Klinische Chemie, Universitätsspital Zürich, 8091 Zürich
Telefon 044/255 34 11, www.MQZH.ch, info@MQZH.ch

Survey Specimens
The homogeneity and stability of all specimens were checked before and/or during shipment and no irregularities were noted. The suitability tests were performed by the laboratories of the Universitätsspital Zürich (University Hospital Zurich) (http://www.uzl.usz.ch/).
The following survey specimens were produced specifically for MQ by a sub-contractor:
B1 Strep A Test, B2 Uricult, H4 Parasitic Hematology, K14 tumor marker

Determination of target values

For each target value, the type of determination per ISO17043: 2010 B2.1 is indicated (column "type"):
a Value known due to production.
b Certified reference value for use with special specimens
c Reference value determined by analysis
d Consensus values of expert laboratories
e Consensus values of the participants

For methods groups with more than 9 participants, consensus values of the participants ("e") are generally determined.
In order to calculate the target values, we use the mean value of the method group. Values that differ more than 1.5 times the QUALAB-tolerance are outliers and are not used to calculate the target value. Starting point for the elimination of outliers are the values of our suitability tests.
In order to provide all participants with target values that are as meaningful as possible, other methods may also be applied for smaller method groups.

Uncertainty of the determined target values
The standard uncertainty (u_x) is calculated using the following formula (ISO13528):
ux = (target value/100) * (1.25/square root of "number of participants") * %CV

- ux has the same unit as the target value
- ux can be compared with the standard deviation of the participants' collective (SD=target value*%CV/100)
- For participant numbers >18, the standard uncertainty (ux) is significantly lower than the scatter of the collective participants and can be neglected.

QUALAB and MQ tolerances

For all mandatory analyzes, QUALAB tolerances are used (www.qualab.ch, external quality control). For non-mandatory analyzes, the tolerances are specified by MQ's survey specimen leader.

If the determined uncertainty, ux, of the target value is greater than 15% of the QUALAB or MQ tolerance, the letter indicating the type of target detection is marked with an additional star (example "e*"). Thereby, we are alerting the participants to the fact that the uncertainty of the target value can have an impact on the evaluation.

Graphics
The results are shown graphically as follows:



Comparison of Devices
The data in this report allows you to compare the performance of different devices. However, remember to consider the following:

- The chemical control K1 is a ready-to-use commercial control serum. Even if the specimen is of human origin, it is possible that matrix effects occur. These are device-specific and result in different target values.
- Only one specimen was measured. Since the scatter of the results is dependent on the nature of the specimen (matrix effects) and on the signal strength, the determined coefficient of variations (CV in %) cannot be applied generally.
- A large number of runaways is due to administrative errors (wrong unit, results mixed up) or to operator errors (wrong sample, not correctly taken up in solution, not mixed well) and has nothing to do with the type of device.

.

Zürich, 12.4.2023

Dr. R. Fried
Survey Director

.

INR



QUALAB tolerance : 15 %

INR ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Innovin	15	100.0	0.0	0.0	1.57	3.4	e
2	Neoplastin R	13	100.0	0.0	0.0	1.72	4.0	e
3	Neoplastin Plus	5	100.0	0.0	0.0	1.99	4.6	e*
4	STA-NeoPTimal	4	75.0	25.0	0.0	2.01	8.0	e*
5	Recombiplastin 2G	12	100.0	0.0	0.0	1.69	5.1	e
6	Other methods	16	93.7	6.3	0.0	1.64	7.3	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Fibrinogen OA



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Siemens Thrombin	9	100.0	0.0	0.0	1.10	6.9	e*
2	Stago/STA	17	100.0	0.0	0.0	1.10	5.3	e
3	Fibrinogen Q.F.A.	6	100.0	0.0	0.0	1.12	3.9	e
4	Other methods	4	100.0	0.0	0.0	1.13	6.6	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Activated Prothrombin Time



QUALAB tolerance : 25 %

Activated Prothrombin Time (Sek)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Actin FS	8	87.5	12.5	0.0	41.9	12.6	e*
2	Pathromtin SL	4	100.0	0.0	0.0	66.9	5.2	e
3	Stago/STA	20	100.0	0.0	0.0	53.7	7.0	e
4	aPTT-SP	7	100.0	0.0	0.0	43.8	7.3	e
5	Other methods	10	90.0	10.0	0.0	42.8	13.8	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

INR CoaguChek



QUALAB tolerance : 15 %
(< 1.3: +/- 0.2)

INR CoaguChek ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CoaguChek Pro II	791	99.3	0.1	0.6	1.2	3.4	e

Prothrombin time NT



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Innovin	11	100.0	0.0	0.0	99	2.1	e
2	Neoplastin R	12	100.0	0.0	0.0	94	5.0	e
3	Neoplastin Plus	6	100.0	0.0	0.0	90	5.9	e*
4	Recombiplastin 2G	9	100.0	0.0	0.0	100	3.4	e
5	Other methods	16	100.0	0.0	0.0	99	1.9	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Faktor II



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	4	100.0	0.0	0.0	98.6	7.9	e*

Fibrinogen N



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Siemens Thrombin	7	100.0	0.0	0.0	2.77	2.1	e
2	Stago/STA	17	100.0	0.0	0.0	2.91	5.5	e
3	Fibrinogen Q.F.A.	8	100.0	0.0	0.0	2.77	5.9	e*
4	Fib Clauss (IL)	4	100.0	0.0	0.0	3.12	6.4	e*
5	Other methods	8	100.0	0.0	0.0	2.82	4.7	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Faktor V



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	8	100.0	0.0	0.0	98.1	9.1	e*

aPTT N



QUALAB tolerance : 25 %

aPTT N (Sek)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Actin FS	9	100.0	0.0	0.0	23.0	2.3	e
2	Stago/STA	21	100.0	0.0	0.0	31.8	6.7	e
3	aPTT-SP	12	100.0	0.0	0.0	25.6	6.1	e
4	Other methods	9	100.0	0.0	0.0	35.0	14.7	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Faktor VII



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	5	100.0	0.0	0.0	104.8	6.4	e

Prothrombin time HT



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Innovin	12	100.0	0.0	0.0	95	3.4	e
2	Neoplastin R	11	100.0	0.0	0.0	100	5.7	e
3	Recombiplastin 2G	12	100.0	0.0	0.0	97	4.8	e
4	Other methods	11	100.0	0.0	0.0	95	6.5	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Anti-FXa (unfrakt-Heparin)



MQ tolerance : 20 %

Anti-FXa (unfrakt-Heparin) (IU/ml)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Stago/STA	11	100.0	0.0	0.0	0.82	9.1	e*
2	ACL	20	100.0	0.0	0.0	0.87	7.0	e
3	Other methods	10	90.0	0.0	10.0	0.93	6.7	e

Fibrinogen H



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Siemens Thrombin	4	100.0	0.0	0.0	3.21	1.8	e
2	Stago/STA	14	100.0	0.0	0.0	3.24	5.8	e
3	Fibrinogen Q.F.A.	14	100.0	0.0	0.0	3.18	6.7	e
4	Other methods	9	100.0	0.0	0.0	3.13	7.6	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

aPTT H



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Actin FS	4	100.0	0.0	0.0	109.3	9.0	e*
2	Actin FSL	4	100.0	0.0	0.0	104.1	1.8	e
3	Stago/STA	13	100.0	0.0	0.0	120.0	0.0	e
4	aPTT-SP	13	100.0	0.0	0.0	120.0	0.0	e
5	Other methods	9	100.0	0.0	0.0	120.0	0.0	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

D-dimer



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	STA Liatest	16	87.4	6.3	6.3	0.47	10.7	e*
2	Siemens Innovance	14	100.0	0.0	0.0	0.75	5.1	e
3	Pathfast	11	100.0	0.0	0.0	1.85	6.0	e
4	ACL	11	100.0	0.0	0.0	0.86	6.4	e
5	AQT 90 FLEX	6	100.0	0.0	0.0	0.29	8.8	e*
6	VIDAS	15	100.0	0.0	0.0	0.46	4.7	e

12 additional results were submitted but not published because the method groups were too small. (< results per group)

CoaguChek APTT



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CoaguChek Pro II	6	100.0	0.0	0.0	41.2	11.3	e*

INR CCXS



QUALAB tolerance : 15 %

INR CCXS ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CoaguChek XS	1516	99.4	0.3	0.3	2.9	3.7	e

INR HC



QUALAB tolerance : 15 %

INR HC ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Hemochron j.	6	50.0	16.7	33.3	1.7	10.9	d

INR MI



QUALAB tolerance : 15 %

INR MI ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	MicroINR	132	84.8	0.8	14.4	2.1	6.5	e

INR Xprecia



QUALAB tolerance : 15 %
(< 1.3: +/- 0.2)

INR Xprecia ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Xprecia	57	96.5	3.5	0.0	1.2	4.8	e

INR Lumira Dx



QUALAB tolerance : 15 %
(< 1.3: +/- 0.2)

INR Lumira Dx ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Lumira Dx	12	100.0	0.0	0.0	1.3	4.0	e

Anti-FXa (LMW-Heparin)



MQ tolerance : 20 %

Anti-FXa (LMW-Heparin) (IU/ml)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Stago/STA	8	100.0	0.0	0.0	1.55	4.8	e
2	ACL	13	100.0	0.0	0.0	1.50	6.1	e
3	Other methods	16	93.7	0.0	6.3	1.75	9.4	e

Anti-FXa (Rivaroxaban)



MQ tolerance : 20 %

Anti-FXa (Rivaroxaban) (µg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Stago/STA	10	100.0	0.0	0.0	70.38	7.8	e*
2	ACL	8	100.0	0.0	0.0	90.75	10.4	a

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Anti-FXa (Apixaban)



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ACL	4	100.0	0.0	0.0	80.75	5.3	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Anti-FXa (Edoxaban)



MQ tolerance : 20 %

Anti-FXa (Edoxaban) (µg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	4	100.0	0.0	0.0	47.50	11.7	e*

Hemoglobin



QUALAB tolerance : 9 %

Hemoglobin (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Automat	16	100.0	0.0	0.0	115.4	3.2	e
2	Cyanmethemoglobin	18	94.4	0.0	5.6	113.8	3.3	e
3	Sysmex X	51	98.0	2.0	0.0	115.2	2.5	e
4	Hemocue	411	94.2	1.9	3.9	115.1	2.6	e
5	Hemocontrol	9	100.0	0.0	0.0	117.0	2.9	e
6	DiaSpect	14	85.8	7.1	7.1	120.9	4.1	e*
7	Sysmex	8	100.0	0.0	0.0	115.0	0.9	e

10 additional results were submitted but not published because the method groups were too small. (< results per group)

Hemoglobin



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex KX21	123	97.6	0.0	2.4	114.7	1.8	e
2	Sysmex PocH - 100i	203	90.6	0.5	8.9	112.9	2.6	e
3	Sysmex XP 300	621	95.5	0.2	4.3	114.2	1.8	e
4	Mythic	248	93.6	3.2	3.2	112.5	3.3	e
5	Sysmex XQ-320	61	96.8	1.6	1.6	115.3	2.3	e
6	Swelab	30	96.7	0.0	3.3	116.7	3.2	e
7	Medonic	4	50.0	25.0	25.0	114.2	9.5	a
8	Celltac Alpha (Nihon	92	90.2	0.0	9.8	116.9	2.2	e
9	Samsung HC10	15	100.0	0.0	0.0	115.2	4.0	e
10	Micros 60	75	92.0	2.7	5.3	112.3	3.1	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Hematocrit



QUALAB tolerance : 9 %

Hematocrit (l/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Automat	13	84.6	0.0	15.4	0.32	4.7	e*
2	Sysmex X	51	96.0	2.0	2.0	0.34	3.0	e
3	Sysmex	8	100.0	0.0	0.0	0.34	3.2	e*

10 additional results were submitted but not published because the method groups were too small. (< results per group)

Hematocrit



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex XQ-320	62	98.4	0.0	1.6	0.32	2.3	e
2	Sysmex KX21	123	99.2	0.0	0.8	0.31	2.3	e
3	Sysmex PocH - 100i	203	88.2	4.4	7.4	0.34	3.5	e
4	Sysmex XP 300	621	97.1	0.6	2.3	0.31	2.6	e
5	Mythic	250	94.0	2.8	3.2	0.33	3.9	e
6	Swelab	30	93.4	3.3	3.3	0.33	3.3	e
7	Medonic	4	50.0	0.0	50.0	0.33	3.4	e*
8	Celltac Alpha (Nihon	92	80.5	5.4	14.1	0.33	4.0	e
9	Samsung HC10	15	100.0	0.0	0.0	0.34	3.4	e
10	Micros 60	75	92.0	1.3	6.7	0.30	3.9	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Erythrocytes



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Automat	13	100.0	0.0	0.0	3.65	3.5	e
2	Sysmex X	51	98.0	0.0	2.0	3.69	3.1	e
3	Sysmex	8	100.0	0.0	0.0	3.67	2.2	e

9 additional results were submitted but not published because the method groups were too small. (< results per group)

Erythrocytes



QUALAB tolerance : 25 %

Erythrocytes (T/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex XQ-320	62	100.0	0.0	0.0	3.77	2.9	e
2	Sysmex KX21	123	100.0	0.0	0.0	3.65	3.1	e
3	Sysmex PocH - 100i	203	93.6	1.0	5.4	3.80	4.8	e
4	Sysmex XP 300	622	98.1	0.6	1.3	3.66	3.5	e
5	Mythic	250	97.6	0.0	2.4	3.58	4.1	e
6	Swelab	30	100.0	0.0	0.0	3.73	4.4	e
7	Medonic	4	75.0	0.0	25.0	3.66	12.1	a
8	Celltac Alpha (Nihon	92	92.4	2.2	5.4	3.70	7.0	e
9	Samsung HC10	15	100.0	0.0	0.0	3.70	2.0	e
10	Micros 60	75	94.7	1.3	4.0	3.50	6.4	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Leucocytes



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Automat	13	100.0	0.0	0.0	3.69	8.2	e
2	Microscopic	8	75.0	0.0	25.0	3.85	15.4	a
3	Sysmex X	51	94.1	3.9	2.0	3.92	9.2	e
4	Sysmex	8	100.0	0.0	0.0	3.91	7.7	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

Leucocytes



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex XQ-320	62	98.4	0.0	1.6	3.98	8.0	e
2	Sysmex KX21	123	95.1	1.6	3.3	3.78	9.2	e
3	Sysmex PocH - 100i	202	93.6	1.0	5.4	3.71	8.3	e
4	Sysmex XP 300	622	93.9	1.6	4.5	3.85	8.6	e
5	Mythic	248	96.4	0.8	2.8	3.69	9.0	e
6	Swelab	30	93.4	3.3	3.3	3.89	9.4	e
7	Medonic	4	100.0	0.0	0.0	3.70	4.9	e
8	Celltac Alpha (Nihon	91	93.4	0.0	6.6	3.82	8.3	e
9	Samsung HC10	15	93.3	0.0	6.7	3.83	6.1	e
10	Micros 60	75	90.7	4.0	5.3	3.51	10.1	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Thrombocytes



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Automat	12	91.7	0.0	8.3	149.9	7.1	e
2	Microscopic	5	60.0	0.0	40.0	148.0	7.1	e*
3	Sysmex X	51	98.0	0.0	2.0	151.7	6.8	e
4	Sysmex	8	100.0	0.0	0.0	143.5	9.7	e*

7 additional results were submitted but not published because the method groups were too small. (< results per group)

Thrombocytes



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex XQ-320	61	98.4	0.0	1.6	151.5	7.0	e
2	Sysmex KX21	123	95.9	4.1	0.0	153.1	9.9	e
3	Sysmex PocH - 100i	203	98.0	1.0	1.0	153.9	8.3	e
4	Sysmex XP 300	621	97.0	1.9	1.1	154.2	8.7	e
5	Mythic	250	95.2	3.6	1.2	144.5	11.9	e
6	Swelab	30	96.7	0.0	3.3	148.8	8.6	e
7	Medonic	4	100.0	0.0	0.0	152.5	15.5	e*
8	Celltac Alpha (Nihon	92	91.3	1.1	7.6	159.0	8.7	e
9	Samsung HC10	15	100.0	0.0	0.0	157.2	9.8	e
10	Micros 60	75	88.0	5.3	6.7	146.6	12.2	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Hemoglobin H2



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Z3	185	93.6	0.5	5.9	117.4	3.0	e
2	Abx Micros	71	85.9	1.4	12.7	117.2	3.4	e
3	Microsemi	867	90.5	1.3	8.2	119.2	2.4	e

Hematocrit H2



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Z3	185	92.5	1.6	5.9	0.35	4.1	e
2	Abx Micros	71	83.1	4.2	12.7	0.32	4.0	e
3	Microsemi	866	88.2	2.1	9.7	0.31	3.3	e

Leucocytes H2



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Z3	185	98.4	0.0	1.6	3.79	7.6	e
2	Abx Micros	70	90.0	2.9	7.1	3.67	10.3	e
3	Microsemi	866	96.1	2.2	1.7	3.77	9.0	e

Thrombocytes H2



QUALAB tolerance : 25 %

Thrombocytes H2 (G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Z3	185	95.7	1.6	2.7	163.2	9.5	e
2	Abx Micros	71	77.5	4.2	18.3	151.3	11.6	e
3	Microsemi	866	91.0	2.9	6.1	157.0	10.7	e

Erythrocytes H2



QUALAB tolerance : 25 %

Erythrocytes H2 (T/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Z3	184	96.2	1.1	2.7	3.77	5.3	e
2	Abx Micros	71	88.7	2.8	8.5	3.79	7.7	e
3	Microsemi	866	93.1	1.7	5.2	3.71	6.0	e

CRP H2



QUALAB tolerance : 21 %

CRP H2 (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Z3	170	76.5	9.4	14.1	20.8	12.8	e
2	Microsemi	856	87.6	6.0	6.4	22.9	10.7	e
3	Abx Micros	12	91.7	0.0	8.3	23.4	10.5	e*
4	ABX Micros CRP200	57	85.9	12.3	1.8	20.1	14.1	e

Hemoglobin BG



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	iStat	12	100.0	0.0	0.0	119.7	2.6	e

Hematocrit



QUALAB tolerance : 9 %

Hematocrit (l/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	iStat	17	100.0	0.0	0.0	0.35	2.6	e
2	EPOC	11	100.0	0.0	0.0	0.34	2.4	e

Hemoglobin



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	103	100.0	0.0	0.0	128.2	1.3	e
2	Advia	4	100.0	0.0	0.0	130.5	1.9	e
3	Beckman	4	100.0	0.0	0.0	127.5	3.0	e*
4	Yumizen/Pentra	14	100.0	0.0	0.0	129.1	2.4	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Hematocrit



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	104	98.1	0.0	1.9	0.40	2.8	a
2	Advia	4	100.0	0.0	0.0	0.39	2.8	e*
3	Beckman	4	100.0	0.0	0.0	0.38	1.2	e
4	Yumizen/Pentra	13	100.0	0.0	0.0	0.37	3.1	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Erythrocytes



QUALAB tolerance : 25 %

Erythrocytes (T/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	105	99.0	0.0	1.0	4.30	1.6	e
2	Advia	4	100.0	0.0	0.0	4.32	1.6	e
3	Beckman	4	100.0	0.0	0.0	4.29	1.2	e
4	Yumizen/Pentra	13	100.0	0.0	0.0	4.23	2.9	e

Leucocytes



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	104	98.1	1.9	0.0	5.33	7.3	e
2	Advia	4	100.0	0.0	0.0	5.08	5.1	e
3	Beckman	4	100.0	0.0	0.0	5.40	14.7	e*
4	Yumizen/Pentra	13	76.9	7.7	15.4	4.59	14.4	e*

Thrombocytes



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	103	99.0	1.0	0.0	207.1	6.0	e
2	Advia	4	100.0	0.0	0.0	175.5	3.8	e
3	Beckman	4	100.0	0.0	0.0	199.5	3.4	e
4	Yumizen/Pentra	13	100.0	0.0	0.0	207.0	6.0	e

Neutrophils



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	104	95.2	1.9	2.9	2.97	7.7	e
2	Advia	4	100.0	0.0	0.0	3.01	5.3	e
3	Beckman	4	75.0	25.0	0.0	2.95	22.0	e*
4	Yumizen/Pentra	12	58.3	16.7	25.0	1.97	19.4	e*

Lymphocytes



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	104	100.0	0.0	0.0	1.81	4.7	e
2	Advia	4	100.0	0.0	0.0	1.57	7.3	e*
3	Beckman	4	100.0	0.0	0.0	2.10	9.5	e*
4	Yumizen/Pentra	12	83.3	0.0	16.7	2.24	8.2	e

Monocytes



MQ tolerance : 40 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	104	100.0	0.0	0.0	0.35	19.0	a
2	Advia	4	100.0	0.0	0.0	0.29	15.6	a
3	Beckman	4	100.0	0.0	0.0	0.15	42.9	a
4	Yumizen/Pentra	12	83.3	0.0	16.7	0.20	44.4	a

Eosinophils



MQ tolerance : 80 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	103	100.0	0.0	0.0	0.13	20.7	e
2	Advia	4	100.0	0.0	0.0	0.12	26.5	e*
3	Beckman	4	100.0	0.0	0.0	0.13	35.0	e*
4	Yumizen/Pentra	12	91.7	0.0	8.3	0.10	41.9	e*

Basophiles



MQ tolerance : 80 %
(< 0.10: +/- 0.08 G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	104	89.4	9.6	1.0	0.10	58.0	a
2	Beckman	4	100.0	0.0	0.0	0.05	60.3	e*
3	Yumizen/Pentra	12	91.7	0.0	8.3	0.05	55.2	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

MCV



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	92	100.0	0.0	0.0	90.2	4.5	e
2	Advia	4	100.0	0.0	0.0	90.3	3.4	e
3	Yumizen/Pentra	9	100.0	0.0	0.0	88.2	2.2	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

MCH



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	93	100.0	0.0	0.0	29.9	1.5	e
2	Advia	4	100.0	0.0	0.0	30.2	2.0	e
3	Yumizen/Pentra	9	100.0	0.0	0.0	31.3	4.3	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

MCHC



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	94	98.9	1.1	0.0	331	5.3	e
2	Advia	4	100.0	0.0	0.0	332	1.8	e
3	Yumizen/Pentra	9	100.0	0.0	0.0	361	4.6	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

RDW



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	89	100.0	0.0	0.0	13.0	2.8	e
2	Yumizen/Pentra	8	100.0	0.0	0.0	13.1	9.4	e*

6 additional results were submitted but not published because the method groups were too small. (< results per group)

Immature Granulocytes



MQ tolerance : 25 %
(< 0.10: +/- 0.10 G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	83	89.2	6.0	4.8	0.04	45.1	a

Reticulocytes



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	56	100.0	0.0	0.0	56.0	10.1	a

6 additional results were submitted but not published because the method groups were too small. (< results per group)

Hämolyseindex Probe A



MQ tolerance : 15 %

Hämolyseindex Probe A ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	23	100.0	0.0	0.0	117.22	5.6	e
2	Abbott	6	100.0	0.0	0.0	0.85	6.1	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Hämolyseindex Probe B



MQ tolerance : 15 %

Hämolyseindex Probe B ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	23	95.7	0.0	4.3	27.55	5.6	e
2	Abbott	6	100.0	0.0	0.0	0.20	5.1	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Erythrocyte sedimentation rate 1h



MQ tolerance : 40 %

Erythrocyte sedimentation rate 1h (mm/h)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	MINI-CUBE	21	100.0	0.0	0.0	120	15.4	e
2	Sarstedt Sedivette	18	100.0	0.0	0.0	64	18.7	e
3	Sarstedt Microvette	5	100.0	0.0	0.0	60	22.3	a
4	BD Seditainer	47	95.8	2.1	2.1	62	13.5	e
5	Other methods	21	95.2	0.0	4.8	64	10.1	e

Erythrocyte sedimentation rate 2h



MQ tolerance : 40 %

Erythrocyte sedimentation rate 2h (mm/2h)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sarstedt Sedivette	6	100.0	0.0	0.0	115	16.1	e*
2	BD Seditainer	4	75.0	25.0	0.0	133	26.7	e*
3	Other methods	6	100.0	0.0	0.0	133	13.0	e*

Hemoglobin HS



MQ tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	PixCell HemoScreen	10	60.0	10.0	30.0	156.1	5.5	e*

Hematocrit HS



MQ tolerance : 9 %

Hematocrit HS (l/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	PixCell HemoScreen	10	50.0	10.0	40.0	0.4	5.8	e*

Erythrocytes HS



MQ tolerance : 25 %

Erythrocytes HS (T/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	PixCell HemoScreen	10	80.0	0.0	20.0	4.32	11.1	e*

Leucocytes HS



MQ tolerance : 25 %

Leucocytes HS (G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	PixCell HemoScreen	10	100.0	0.0	0.0	7.04	10.7	e*

Trombocytes HS



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	PixCell HemoScreen	10	100.0	0.0	0.0	253.0	3.3	e

CRP



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas b101	363	98.6	0.0	1.4	22.7	5.6	e
2	IChroma	5	100.0	0.0	0.0	35.0	8.3	e*
3	Cobas	36	100.0	0.0	0.0	24.1	5.3	e
4	Turbidimetry	18	88.9	0.0	11.1	25.0	9.9	e
5	Afinion	1151	99.5	0.2	0.3	25.5	5.3	e
6	NycoCard SingleTest-	68	88.2	5.9	5.9	24.0	11.5	e
7	Quick Read go	94	94.6	4.3	1.1	24.5	9.0	e
8	Eurolyser	84	75.0	4.8	20.2	34.2	10.1	e
9	Fuji Dri-Chem	12	91.7	0.0	8.3	27.2	11.7	e*
10	Autolyser/DiaSys	11	81.8	0.0	18.2	23.3	10.7	e*
11	Piccolo	6	66.6	16.7	16.7	29.1	15.7	e*
12	Nephelometry	4	100.0	0.0	0.0	18.5	9.4	e*
13	Celltac chemi	46	100.0	0.0	0.0	24.4	4.2	e

CRP



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	QuikRead (Vollblut)	21	95.2	0.0	4.8	39.2	6.0	e

CRP



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Spinit	13	100.0	0.0	0.0	23.7	7.5	e
2	Abbott	11	100.0	0.0	0.0	26.2	3.0	e
3	AQT 90 FLEX	6	100.0	0.0	0.0	27.0	7.1	e*
4	Spotchem D-Concept	6	100.0	0.0	0.0	28.8	5.3	e
5	Other methods	4	100.0	0.0	0.0	26.3	2.8	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

IgG



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Turbidimetry	20	100.0	0.0	0.0	19.27	3.5	e
2	Nephelometry	4	100.0	0.0	0.0	18.95	2.8	e
3	Other methods	5	100.0	0.0	0.0	18.50	5.3	e*

IgA



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Turbidimetry	18	100.0	0.0	0.0	2.95	3.7	e
2	Nephelometry	5	100.0	0.0	0.0	3.18	3.3	e
3	Other methods	4	100.0	0.0	0.0	2.91	6.3	e*

IgM



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Turbidimetry	19	100.0	0.0	0.0	1.40	4.0	e
2	Nephelometry	5	100.0	0.0	0.0	1.46	4.4	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

IgE



QUALAB tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	6	100.0	0.0	0.0	112	14.1	e*
2	Cobas	6	100.0	0.0	0.0	142	8.8	e

Alpha-1-Antitrypsin



MQ tolerance : 25 %

Alpha-1-Antitrypsin (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	8	100.0	0.0	0.0	1.78	5.4	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Anti-Streptolysin-Antibodies



MQ tolerance : 25 %

Anti-Streptolysin-Antibodies (kIU/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	11	100.0	0.0	0.0	304	3.7	e
2	Other methods	6	100.0	0.0	0.0	215	4.1	e

Complement C3



QUALAB tolerance : 15 %

Complement C3 (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	19	100.0	0.0	0.0	2.24	4.1	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Complement C4



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Alinity	5	100.0	0.0	0.0	0.42	4.0	e
2	Other methods	15	100.0	0.0	0.0	0.40	6.9	e

Haptoglobin



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	27	100.0	0.0	0.0	1.86	2.8	e

Transferrin



MQ tolerance : 25 %

Transferrin (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	33	100.0	0.0	0.0	3.49	2.2	e

Beta-2 microglobuline



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	9	100.0	0.0	0.0	3.00	3.6	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Rheumatoid factor



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Architect	6	100.0	0.0	0.0	42.0	2.9	e
2	Other methods	5	100.0	0.0	0.0	43.1	2.5	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Ceruloplasmin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Siemens	8	100.0	0.0	0.0	460.00	4.8	e
2	Other methods	4	100.0	0.0	0.0	360.00	3.5	e

Prealbumin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	17	94.1	5.9	0.0	322.72	8.9	e

Soluble transferrin receptor



MQ tolerance : 25 %

Soluble transferrin receptor (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	11	100.0	0.0	0.0	4.2	1.2	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

free light chain kappa



QUALAB tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Freelite	11	100.0	0.0	0.0	20.90	4.1	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

free light chain lambda



QUALAB tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Freelite	11	100.0	0.0	0.0	18.35	3.3	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

IgE peanut qn



MQ tolerance : 30 %
(< 1.50: +/- 0.45 kU/L)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	14	100.0	0.0	0.0	0.13	76.3	e*

IgE birch qn



QUALAB tolerance : 30 %
(< 1.50: +/- 0.45 kU/L)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	14	100.0	0.0	0.0	0.13	70.9	e*

IgE cat qn



QUALAB tolerance : 30 %
(< 1.50: +/- 0.45 kU/L)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	13	100.0	0.0	0.0	0.12	86.2	e*

IgE total



QUALAB tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	13	84.6	0.0	15.4	12	13.3	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

IgE sx1 qn



MQ tolerance : 30 %
(< 1.50: +/- 0.45 kU/L)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	10	100.0	0.0	0.0	0.15	48.6	e*

IgE fx5 qn



MQ tolerance : 30 %
(< 1.50: +/- 0.45 kU/L)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	11	100.0	0.0	0.0	0.11	72.6	e*

IgE rx1qn



MQ tolerance : 30 %
(< 1.50: +/- 0.45 kU/L)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	8	100.0	0.0	0.0	0.11	61.0	e*

IgE rx2 qn



MQ tolerance : 30 %
(< 1.50: +/- 0.45 kU/L)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	8	100.0	0.0	0.0	0.10	81.5	e*

IgE D. pteronyssinus qn



QUALAB tolerance : 30 %
(< 1.50: +/- 0.45 kU/L)

IgE D. pteronyssinus qn (kU/L)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	11	100.0	0.0	0.0	0.14	74.6	e*

CRP HS



QUALAB tolerance : 21 %
(< 10.00: +/- 2.00 mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Turbidimetry	9	100.0	0.0	0.0	1.20	17.6	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Lipoprotein (a)



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	6	100.0	0.0	0.0	29	11.0	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

CRP



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	AFIAS	135	93.3	3.0	3.7	22.4	8.7	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Anti deam. Gliadin IgA



MQ tolerance : 30 %

Anti deam. Gliadin IgA (U/ml)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	4	100.0	0.0	0.0	4.30	4.5	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Anti tTG IgA



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	6	100.0	0.0	0.0	101.00	17.3	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

CRP Lumira



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Lumira Dx	13	84.6	0.0	15.4	85.4	10.9	a

Albumine



QUALAB tolerance : 12 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	14	100.0	0.0	0.0	33	4.4	e
2	Cobas	28	100.0	0.0	0.0	35	2.9	e
3	Fuji Dri-Chem	257	98.0	0.8	1.2	40	4.3	e
4	Spotchem SP-4430	31	93.5	0.0	6.5	36	4.9	e
5	Spotchem D-Concept	216	96.3	2.8	0.9	39	5.8	e
6	Piccolo	63	96.8	0.0	3.2	36	3.8	e
7	Beckmann	5	100.0	0.0	0.0	34	2.1	e
8	Skyla	9	100.0	0.0	0.0	35	5.0	e*
9	Selectra Pro	13	100.0	0.0	0.0	35	4.3	e
10	Autolyser/DiaSys	8	100.0	0.0	0.0	35	2.5	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

Alkaline phosphatase



QUALAB tolerance : 18 %

Alkaline phosphatase (U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	IFCC	13	100.0	0.0	0.0	170	4.8	e
2	Cobas	30	100.0	0.0	0.0	158	5.4	e
3	Reflotron	85	91.7	5.9	2.4	191	8.2	e
4	Fuji Dri-Chem	1021	98.9	0.6	0.5	163	5.9	e
5	Spotchem SP-4430	86	97.7	2.3	0.0	122	6.3	e
6	Spotchem D-Concept	487	98.8	0.6	0.6	151	6.1	e
7	Beckman	6	100.0	0.0	0.0	191	3.2	e
8	Dimension	4	100.0	0.0	0.0	156	2.5	e
9	Piccolo	57	100.0	0.0	0.0	184	3.3	e
10	Selectra Pro	16	87.5	0.0	12.5	195	5.3	e
11	Skyla	12	75.0	16.7	8.3	141	10.4	e*
12	Autolyser/DiaSys	21	100.0	0.0	0.0	175	7.3	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Amylase



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	9	100.0	0.0	0.0	150	1.9	e
2	Reflotron	21	100.0	0.0	0.0	162	7.5	e
3	Fuji Dri-Chem	755	99.2	0.5	0.3	158	3.9	e
4	Spotchem SP-4430	59	96.6	1.7	1.7	185	6.9	e
5	Spotchem D-Concept	365	99.7	0.3	0.0	168	6.3	e
6	Skyla	7	71.4	14.3	14.3	153	8.1	e*
7	Abbott	6	100.0	0.0	0.0	163	1.0	e
8	Beckman	4	100.0	0.0	0.0	158	2.5	e
9	Piccolo	60	98.3	0.0	1.7	131	2.9	e
10	Selectra Pro	10	100.0	0.0	0.0	185	6.4	e
11	Autolyser/DiaSys	8	87.5	12.5	0.0	144	8.8	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Pancreatic amylase



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	IFCC	12	100.0	0.0	0.0	123	2.3	e
2	Cobas	14	100.0	0.0	0.0	121	1.5	e
3	Reflotron	63	96.8	1.6	1.6	135	7.7	e
4	Autolyser/DiaSys	11	100.0	0.0	0.0	115	1.9	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Bilirubin



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	17	100.0	0.0	0.0	60.5	6.8	e
2	Cobas	29	93.1	6.9	0.0	54.1	6.6	e
3	Reflotron	48	87.5	4.2	8.3	51.4	8.0	e
4	Fuji Dri-Chem	831	98.8	0.4	0.8	56.4	5.0	e
5	Spotchem SP-4430	76	92.2	3.9	3.9	57.8	6.9	e
6	Spotchem D-Concept	394	98.5	1.0	0.5	44.0	5.8	e
7	Dimension	4	100.0	0.0	0.0	60.7	2.9	e
8	Beckman	7	100.0	0.0	0.0	62.5	6.6	e*
9	Piccolo	64	98.4	0.0	1.6	57.1	4.1	e
10	Skyla	10	90.0	10.0	0.0	63.7	11.1	e*
11	Selectra Pro	16	93.7	6.3	0.0	54.1	7.9	e
12	Autolyser/DiaSys	18	100.0	0.0	0.0	60.1	4.4	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Bilirubin direct



MQ tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Autolyser/DiaSys	8	100.0	0.0	0.0	28.7	5.6	e
2	Fuji Dri-Chem	29	86.2	0.0	13.8	32.0	6.5	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Calcium



QUALAB tolerance : 9 %
(< 2.00: +/- 0.18 mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	26	100.0	0.0	0.0	2.48	2.0	e
2	Cobas	30	100.0	0.0	0.0	2.50	1.4	e
3	Fuji Dri-Chem	332	96.4	1.5	2.1	2.58	4.0	e
4	Spotchem SP-4430	15	100.0	0.0	0.0	2.45	3.9	e
5	Spotchem D-Concept	81	90.1	7.4	2.5	1.92	5.5	e
6	Piccolo	57	98.2	0.0	1.8	2.52	2.3	e
7	Selectra Pro	8	100.0	0.0	0.0	2.46	3.3	e*
8	Autolyser/DiaSys	9	100.0	0.0	0.0	2.50	4.8	a

6 additional results were submitted but not published because the method groups were too small. (< results per group)

Calcium ISE



MQ tolerance : 12 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	iStat Chem8	5	100.0	0.0	0.0	1.08	1.1	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Chloride



QUALAB tolerance : 6 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ISE	32	93.8	3.1	3.1	99	2.0	e
2	Cobas	19	100.0	0.0	0.0	96	1.1	e
3	Fuji Dri-Chem	933	98.0	0.9	1.1	97	2.1	e
4	Spotchem D-Concept	419	98.6	0.7	0.7	103	2.1	e
5	Standard chemistry	4	100.0	0.0	0.0	98	1.8	e*
6	Spotchem EL-SE 1520	72	90.3	1.4	8.3	105	2.4	e
7	Piccolo	26	100.0	0.0	0.0	99	2.2	e
8	iStat Chem8	5	100.0	0.0	0.0	100	1.1	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Cholesterol total



QUALAB tolerance : 10 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	26	100.0	0.0	0.0	4.91	3.0	e
2	Cobas	26	100.0	0.0	0.0	4.82	2.3	e
3	Reflotron	37	97.3	2.7	0.0	4.68	4.2	e
4	Fuji Dri-Chem	972	97.4	1.7	0.9	4.63	4.0	e
5	Spotchem SP-4430	83	98.8	0.0	1.2	4.58	3.4	e
6	Spotchem D-Concept	432	98.6	0.5	0.9	4.65	3.0	e
7	Piccolo	23	100.0	0.0	0.0	4.81	1.4	e
8	Skyla	10	80.0	10.0	10.0	4.76	5.2	e*
9	Cholestech LDX	293	95.6	2.7	1.7	4.67	4.2	e
10	Selectra Pro	15	93.3	6.7	0.0	4.99	4.5	e
11	Autolyser/DiaSys	21	95.2	4.8	0.0	4.90	4.5	e
12	Other methods	4	100.0	0.0	0.0	4.60	3.4	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Cholesterin HDL



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Wet chemistry, direc	8	100.0	0.0	0.0	1.22	3.6	e
2	Cobas	25	100.0	0.0	0.0	0.82	4.2	e
3	Reflotron	16	81.2	6.3	12.5	0.83	11.1	e*
4	Fuji Dri-Chem	937	99.1	0.2	0.7	1.08	4.0	e
5	Spotchem SP-4430	75	93.3	4.0	2.7	0.77	8.1	e
6	Spotchem D-Concept	418	97.1	1.7	1.2	0.78	8.9	e
7	Dimension	4	100.0	0.0	0.0	1.13	5.6	e*
8	Piccolo	22	100.0	0.0	0.0	0.85	9.0	e
9	Skyla	8	87.5	12.5	0.0	1.29	13.5	e*
10	Pentra/Selectra	8	75.0	12.5	12.5	0.95	15.7	e*
11	Cholestech LDX	293	91.8	2.7	5.5	0.87	9.1	e
12	Selectra Pro	4	100.0	0.0	0.0	0.96	6.6	e*
13	Architect	13	100.0	0.0	0.0	1.21	2.8	e
14	Autolyser/DiaSys	21	90.5	9.5	0.0	1.05	11.8	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Creatine kinase



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	IFCC	18	100.0	0.0	0.0	318	2.9	e
2	Cobas	27	100.0	0.0	0.0	302	3.0	e
3	Reflotron	4	100.0	0.0	0.0	300	3.8	e
4	Fuji Dri-Chem	672	97.5	1.8	0.7	349	5.1	e
5	Spotchem SP-4430	46	97.8	2.2	0.0	320	6.4	e
6	Spotchem D-Concept	287	99.0	0.3	0.7	293	7.6	e
7	Piccolo	22	100.0	0.0	0.0	308	4.9	e
8	Skyla	8	87.5	12.5	0.0	286	8.5	e*
9	Selectra Pro	11	100.0	0.0	0.0	336	3.8	e
10	Dimension	4	100.0	0.0	0.0	306	0.3	e
11	Autolyser/DiaSys	18	100.0	0.0	0.0	311	3.6	e
12	Other methods	4	100.0	0.0	0.0	319	2.8	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Cholesterol LDL



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Selectra	6	83.3	16.7	0.0	3.2	13.3	e*
2	Standard chemistry	15	100.0	0.0	0.0	3.2	2.9	e
3	Roche, Cobas	15	100.0	0.0	0.0	3.1	2.3	e
4	Autolyser/DiaSys	12	83.4	8.3	8.3	3.0	10.3	e*
5	Beckman	4	100.0	0.0	0.0	3.4	9.4	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Iron



QUALAB tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	14	100.0	0.0	0.0	28	3.0	e
2	Cobas	17	100.0	0.0	0.0	27	1.4	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Gamma-glutamyltransferase



QUALAB tolerance : 18 %

Gamma-glutamyltransferase (U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	30	100.0	0.0	0.0	76	6.6	e
2	Reflotron	122	96.7	0.8	2.5	106	7.4	e
3	Fuji Dri-Chem	1132	99.2	0.3	0.5	97	5.2	e
4	Spotchem SP-4430	124	97.6	1.6	0.8	97	7.5	e
5	Spotchem D-Concept	556	99.0	0.5	0.5	94	6.5	e
6	Selectra/Biolis	4	100.0	0.0	0.0	80	7.4	e*
7	Abbott	15	100.0	0.0	0.0	77	8.5	e*
8	IFCC Beckmann	6	100.0	0.0	0.0	80	0.9	e
9	Piccolo	64	100.0	0.0	0.0	72	3.8	e
10	Skyla	11	100.0	0.0	0.0	72	7.7	e*
11	Selectra Pro	12	100.0	0.0	0.0	80	2.9	e
12	Autolyser/DiaSys	21	100.0	0.0	0.0	82	4.4	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

Glucose



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	26	100.0	0.0	0.0	10.0	2.7	e
2	Cobas	29	100.0	0.0	0.0	10.0	2.1	e
3	Reflotron	119	89.9	5.9	4.2	9.8	4.6	e
4	Fuji Dri-Chem	1068	98.7	0.5	0.8	9.4	2.4	e
5	Spotchem SP-4430	105	88.6	9.5	1.9	9.9	5.2	e
6	Spotchem D-Concept	524	94.8	4.8	0.4	9.3	4.3	e
7	Dimension	4	100.0	0.0	0.0	10.2	1.6	e
8	Piccolo	77	100.0	0.0	0.0	9.8	1.5	e
9	Cholestech LDX	286	96.5	2.1	1.4	9.2	3.8	e
10	Selectra Pro	17	88.2	0.0	11.8	10.0	3.3	e
11	Autolyser/DiaSys	19	94.7	5.3	0.0	9.7	4.2	e
12	Other methods	7	85.7	0.0	14.3	9.7	3.3	e*
13	iStat Chem8	7	100.0	0.0	0.0	9.2	1.2	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Glucose



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Accu-Chek Instant	119	94.9	3.4	1.7	9.3	3.5	e
2	Accu-Chek Aviva	147	89.8	4.1	6.1	10.7	4.1	e
3	Accu-Chek Inform 2	898	97.8	2.0	0.2	11.2	3.6	e
4	Accu-Check Guide	271	95.2	2.6	2.2	9.1	3.6	e
5	Contour XT	1358	93.9	3.4	2.7	10.3	4.3	e
6	Skyla	13	92.3	0.0	7.7	10.3	2.1	e
7	Statstrip/Xpress	101	99.0	0.0	1.0	9.1	3.1	e
8	Glucocard	10	70.0	10.0	20.0	14.2	5.7	e*
9	Hemocue 201+ P-equiv	111	95.5	1.8	2.7	11.1	3.0	e
10	Hemocue 201RT P-equi	134	94.8	1.5	3.7	11.0	2.6	e
11	Freestyle Freedom li	4	100.0	0.0	0.0	10.7	3.9	e*
12	Contour NEXT	23	82.6	8.7	8.7	9.8	5.9	e*

7 additional results were submitted but not published because the method groups were too small. (< results per group)

Glucose B



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Hemocue 201+ (alt)	35	100.0	0.0	0.0	10.9	2.8	e
2	OneTouch Verio	24	100.0	0.0	0.0	9.8	3.5	e
3	Contour 2 (5s)	11	81.8	0.0	18.2	8.2	5.1	e*
4	Healthpro	24	83.3	0.0	16.7	16.3	4.5	e
5	Mylife UNIO	461	94.6	4.1	1.3	11.9	4.1	e
6	mylife Pura	95	92.6	5.3	2.1	11.2	4.5	e
7	Alpha Check	8	75.0	25.0	0.0	15.2	5.7	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Uric Acid



QUALAB tolerance : 12 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	28	100.0	0.0	0.0	367	2.3	e
2	Cobas	26	100.0	0.0	0.0	360	1.8	e
3	Reflotron	67	95.5	1.5	3.0	384	4.6	e
4	Fuji Dri-Chem	1054	98.0	0.6	1.4	405	2.7	e
5	Spotchem SP-4430	102	95.1	2.9	2.0	335	4.6	e
6	Spotchem D-Concept	520	99.6	0.2	0.2	346	3.6	e
7	Piccolo	42	90.4	4.8	4.8	328	6.0	e
8	Skyla	13	92.3	0.0	7.7	368	2.8	e
9	Selectra Pro	17	100.0	0.0	0.0	356	5.4	e
10	Autolyser/DiaSys	20	95.0	5.0	0.0	354	5.0	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Urea



QUALAB tolerance : 15 %

Urea (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	25	100.0	0.0	0.0	15.1	4.0	e
2	Cobas	27	100.0	0.0	0.0	14.5	2.6	e
3	Reflotron	36	94.4	0.0	5.6	15.6	4.2	e
4	Fuji Dri-Chem	642	98.7	0.2	1.1	15.3	2.4	e
5	Spotchem SP-4430	59	96.6	1.7	1.7	13.8	7.7	e
6	Spotchem D-Concept	295	91.2	6.8	2.0	14.8	8.1	e
7	Piccolo	66	100.0	0.0	0.0	14.0	2.4	e
8	Skyla	13	92.3	7.7	0.0	14.0	7.5	e*
9	Selectra Pro	10	100.0	0.0	0.0	14.2	6.8	e*
10	Autolyser/DiaSys	16	100.0	0.0	0.0	14.9	4.5	e
11	Other methods	4	100.0	0.0	0.0	14.6	6.9	e*
12	iStat Chem8	6	100.0	0.0	0.0	19.6	2.1	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Potassium



QUALAB tolerance : 6 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ISE	43	97.7	0.0	2.3	4.72	1.9	e
2	Cobas	29	100.0	0.0	0.0	4.77	1.2	e
3	Reflotron	104	82.6	8.7	8.7	4.98	3.4	e
4	Fuji Dri-Chem	1106	97.5	1.1	1.4	4.65	1.8	e
5	Spotchem D-Concept	524	99.0	0.4	0.6	4.48	1.6	e
6	Autolyser/DiaSys	8	75.0	0.0	25.0	4.67	1.6	e
7	Spotchem EL-SE 1520	90	93.4	2.2	4.4	4.48	1.9	e
8	Piccolo	40	65.0	30.0	5.0	5.00	4.3	e
9	iStat Chem8	8	100.0	0.0	0.0	4.65	1.1	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Creatinine



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	13	100.0	0.0	0.0	278	5.4	e
2	Cobas	30	100.0	0.0	0.0	270	3.5	e
3	Reflotron	171	93.6	3.5	2.9	308	7.4	e
4	Fuji Dri-Chem	1160	99.1	0.0	0.9	256	3.9	e
5	Spotchem SP-4430	140	100.0	0.0	0.0	268	3.5	e
6	Spotchem D-Concept	559	99.4	0.2	0.4	257	2.7	e
7	Enzymatic	11	100.0	0.0	0.0	284	4.2	e
8	Piccolo	72	97.2	0.0	2.8	275	4.4	e
9	Selectra Pro	18	100.0	0.0	0.0	278	6.1	e
10	Skyla	12	100.0	0.0	0.0	275	3.3	e
11	Autolyser/DiaSys	21	100.0	0.0	0.0	280	3.9	e
12	Other methods	4	100.0	0.0	0.0	275	2.2	e
13	EPOC	11	81.8	0.0	18.2	257	5.6	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Creatinine E



QUALAB tolerance : 18 %

Creatinine E (µmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	iStat Chem8	21	100.0	0.0	0.0	309	2.2	e
2	ABL700/800	10	100.0	0.0	0.0	289	6.0	e

eGFR CKD-EPI



MQ tolerance : 30 %

eGFR CKD-EPI ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	62	96.8	1.6	1.6	23	10.4	e
2	Reflotron	51	90.2	0.0	9.8	22	10.3	e
3	Fuji Dri-Chem	429	95.4	0.9	3.7	26	7.5	e
4	Spotchem	259	94.2	2.3	3.5	26	8.5	e

eGFR Cockcroft-Gault



MQ tolerance : 30 %

eGFR Cockcroft-Gault ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	4	75.0	25.0	0.0	39	25.1	e*
2	Reflotron	7	85.7	14.3	0.0	37	20.7	e*
3	Fuji Dri-Chem	35	54.3	0.0	45.7	28	10.7	e
4	Spotchem	13	53.8	0.0	46.2	25	7.4	e

LDH



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	IFCC	39	100.0	0.0	0.0	222	4.5	e
2	Cobas	12	100.0	0.0	0.0	227	3.0	e
3	Fuji Dri-Chem	144	94.4	2.1	3.5	191	6.7	e
4	Spotchem SP-4430	14	100.0	0.0	0.0	177	7.1	e
5	Spotchem D-Concept	49	87.8	2.0	10.2	200	6.8	e
6	Autolyser/DiaSys	7	100.0	0.0	0.0	241	6.4	e*

7 additional results were submitted but not published because the method groups were too small. (< results per group)

Magnesium



QUALAB tolerance : 12 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	20	95.0	0.0	5.0	1.02	2.3	e
2	Cobas	19	100.0	0.0	0.0	1.05	2.2	e
3	Fuji Dri-Chem	93	96.7	2.2	1.1	1.07	3.9	e
4	Spotchem D-Concept	41	95.1	4.9	0.0	0.94	4.9	e
5	Spotchem SP-4430	5	80.0	0.0	20.0	0.90	1.9	e
6	Beckman	5	100.0	0.0	0.0	1.07	6.0	e*
7	Piccolo	4	100.0	0.0	0.0	1.06	4.7	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Sodium



QUALAB tolerance : 6 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ISE	42	100.0	0.0	0.0	140	1.5	e
2	Cobas	29	100.0	0.0	0.0	139	1.1	e
3	Fuji Dri-Chem	1015	98.0	0.7	1.3	141	1.5	e
4	Spotchem D-Concept	463	98.7	0.2	1.1	137	1.3	e
5	Spotchem EL-SE 1520	78	100.0	0.0	0.0	135	1.8	e
6	Piccolo	40	100.0	0.0	0.0	137	1.7	e
7	iStat Chem8	7	100.0	0.0	0.0	138	0.4	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Phosphate



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	22	100.0	0.0	0.0	1.4	3.0	e
2	Cobas	23	100.0	0.0	0.0	1.4	2.3	e
3	Fuji Dri-Chem	82	97.6	0.0	2.4	1.5	3.5	e
4	Spotchem D-Concept	14	100.0	0.0	0.0	1.5	4.4	e
5	Spotchem SP-4430	5	80.0	0.0	20.0	1.4	5.4	e*
6	Piccolo	7	71.4	0.0	28.6	1.7	3.3	e

8 additional results were submitted but not published because the method groups were too small. (< results per group)

Protein total



QUALAB tolerance : 12 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	24	100.0	0.0	0.0	53.8	3.8	e
2	Cobas	24	100.0	0.0	0.0	53.1	2.6	e
3	Fuji Dri-Chem	205	98.0	0.5	1.5	51.0	3.5	e
4	Spotchem SP-4430	27	96.3	0.0	3.7	51.5	4.7	e
5	Spotchem D-Concept	170	93.5	5.3	1.2	49.0	5.4	e
6	Piccolo	53	94.3	0.0	5.7	55.0	1.6	e
7	Skyla	11	90.9	0.0	9.1	52.9	4.6	e
8	Selectra Pro	9	88.9	0.0	11.1	54.9	5.9	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Aspartate aminotransferase



QUALAB tolerance : 18 %

Aspartate aminotransferase (U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	IFCC with PP	27	100.0	0.0	0.0	132	3.0	e
2	Cobas	27	100.0	0.0	0.0	133	2.8	e
3	Reflotron	124	91.1	1.6	7.3	153	7.1	e
4	Fuji Dri-Chem	1141	98.8	0.7	0.5	131	4.3	e
5	Spotchem SP-4430	133	99.2	0.8	0.0	105	4.8	e
6	Spotchem D-Concept	554	99.4	0.4	0.2	108	4.1	e
7	Piccolo	78	98.7	0.0	1.3	123	2.4	e
8	Skyla	13	92.3	7.7	0.0	130	6.9	e
9	Selectra Pro	17	100.0	0.0	0.0	140	4.7	e
10	Autolyser/DiaSys	21	100.0	0.0	0.0	136	5.1	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Alanine aminotransferase



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	IFCC with PP	22	100.0	0.0	0.0	93	3.4	e
2	Cobas	30	100.0	0.0	0.0	91	2.6	e
3	Reflotron	124	92.0	4.0	4.0	82	7.3	e
4	Fuji Dri-Chem	1152	98.2	0.8	1.0	97	5.1	e
5	Spotchem SP-4430	133	99.2	0.0	0.8	70	5.6	e
6	Spotchem D-Concept	563	99.6	0.4	0.0	60	5.0	e
7	Piccolo	76	97.4	0.0	2.6	82	4.1	e
8	Skyla	13	92.3	0.0	7.7	84	9.2	e*
9	Selectra Pro	17	100.0	0.0	0.0	96	3.7	e
10	Autolyser/DiaSys	21	100.0	0.0	0.0	95	5.0	e
11	Other methods	5	100.0	0.0	0.0	101	2.1	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Triglycerides



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	25	100.0	0.0	0.0	1.65	4.7	e
2	Cobas	26	100.0	0.0	0.0	1.72	2.7	e
3	Reflotron	15	86.7	0.0	13.3	1.85	9.7	e*
4	Fuji Dri-Chem	959	97.9	1.1	1.0	1.68	5.1	e
5	Spotchem SP-4430	78	100.0	0.0	0.0	1.66	4.4	e
6	Spotchem D-Concept	422	97.6	0.0	2.4	1.73	4.7	e
7	Piccolo	21	100.0	0.0	0.0	1.90	1.4	e
8	Skyla	8	100.0	0.0	0.0	1.77	7.4	e*
9	Cholestech LDX	293	99.4	0.3	0.3	1.57	3.7	e
10	Selectra Pro	14	100.0	0.0	0.0	1.73	4.2	e
11	Autolyser/DiaSys	21	95.2	4.8	0.0	1.57	8.0	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Lithium



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas Integra 800/40	4	100.0	0.0	0.0	1.21	2.2	e
2	Other methods	18	94.4	0.0	5.6	1.22	4.0	e

Lactate



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	16	100.0	0.0	0.0	3.65	4.6	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

HbA1c sample A



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	18	100.0	0.0	0.0	6.1	3.8	e
2	HPLC	8	100.0	0.0	0.0	6.1	3.8	e*
3	Afinion	564	99.6	0.4	0.0	6.0	2.8	e
4	Cobas b101	163	97.0	1.8	1.2	5.8	3.4	e
5	DCA2000/Vantage	86	96.5	1.2	2.3	6.2	3.4	e
6	Celltac chemi	22	95.5	4.5	0.0	5.8	5.2	e*
7	NycoCard	10	90.0	0.0	10.0	6.2	4.7	e*
8	Eurolyser	8	87.5	0.0	12.5	5.9	2.9	e
9	A1c Now	215	85.6	9.3	5.1	5.7	5.6	e
10	AFIAS	83	91.6	6.0	2.4	6.0	4.9	e
11	Others	26	88.5	7.7	3.8	6.1	4.9	e
12	Spinit	14	92.9	0.0	7.1	6.1	4.1	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

HbA1c sample B



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	17	100.0	0.0	0.0	6.0	3.2	e
2	HPLC	9	100.0	0.0	0.0	6.0	2.6	e
3	Afinion	780	99.6	0.1	0.3	6.0	2.5	e
4	Cobas b101	183	98.9	1.1	0.0	5.7	3.5	e
5	DCA2000/Vantage	121	99.2	0.0	0.8	6.0	3.2	e
6	Celltac chemi	16	81.2	18.8	0.0	5.5	4.9	e*
7	NycoCard	8	100.0	0.0	0.0	6.3	3.0	e
8	Eurolyser	5	100.0	0.0	0.0	5.8	2.3	e
9	A1c Now	8	75.0	25.0	0.0	5.8	6.2	e*
10	AFIAS	111	97.3	0.9	1.8	6.1	4.5	e
11	Spinit	16	100.0	0.0	0.0	6.1	4.2	e
12	Others	21	95.2	4.8	0.0	6.0	4.8	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

pCO2



QUALAB tolerance : 12 %

pCO2 (kPa)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	98	100.0	0.0	0.0	5.42	2.5	e
2	ABL80 FLEX	4	100.0	0.0	0.0	5.59	4.5	e*
3	ABL80 FLEX CO-OX / O	5	100.0	0.0	0.0	5.77	4.0	e*
4	ABL90 FLEX / PLUS	114	99.1	0.0	0.9	5.66	2.3	e
5	Cobas b 123	14	100.0	0.0	0.0	5.69	0.7	e
6	Cobas b 221	9	100.0	0.0	0.0	5.93	3.9	e
7	GEM	6	100.0	0.0	0.0	5.70	2.3	e
8	iStat	44	97.7	0.0	2.3	4.95	3.5	e
9	EPOC	52	98.1	0.0	1.9	5.22	3.5	e
10	IL	4	100.0	0.0	0.0	5.65	2.5	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

pO2



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	97	99.0	0.0	1.0	14.83	3.1	e
2	ABL80 FLEX	4	100.0	0.0	0.0	15.15	3.3	e
3	ABL80 FLEX CO-OX / O	5	100.0	0.0	0.0	14.00	6.2	e*
4	ABL90 FLEX / PLUS	115	96.6	1.7	1.7	13.70	3.8	e
5	Cobas b 123	16	100.0	0.0	0.0	14.54	4.5	e
6	Cobas b 221	5	100.0	0.0	0.0	16.15	4.7	e*
7	GEM	6	100.0	0.0	0.0	14.75	4.7	e*
8	iStat	42	92.8	4.8	2.4	15.69	7.1	e
9	EPOC	52	92.3	1.9	5.8	14.74	6.6	e
10	IL	4	100.0	0.0	0.0	14.35	2.9	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

pH



QUALAB tolerance : 1 %

pH ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	97	100.0	0.0	0.0	7.39	0.1	e
2	ABL80 FLEX	5	100.0	0.0	0.0	7.40	0.3	e*
3	ABL80 FLEX CO-OX / O	5	100.0	0.0	0.0	7.40	0.1	e
4	ABL90 FLEX / PLUS	115	100.0	0.0	0.0	7.39	0.1	e
5	Cobas b 123	15	100.0	0.0	0.0	7.41	0.1	e
6	Cobas b 221	9	100.0	0.0	0.0	7.39	0.1	e
7	GEM	6	100.0	0.0	0.0	7.42	0.1	e
8	iStat	45	100.0	0.0	0.0	7.43	0.1	e
9	EPOC	51	100.0	0.0	0.0	7.38	0.2	e
10	IL	4	100.0	0.0	0.0	7.42	0.1	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Glucose BG



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas b 221	4	100.0	0.0	0.0	6.1	1.4	e
2	Cobas b 123	10	100.0	0.0	0.0	5.4	3.2	e
3	iStat	10	100.0	0.0	0.0	5.3	2.0	e
4	EPOC	40	92.5	7.5	0.0	5.6	3.7	e
5	ABL700/800	88	100.0	0.0	0.0	5.7	2.1	e
6	ABL90 FLEX / PLUS	100	100.0	0.0	0.0	5.6	1.5	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

Hemoglobin BG



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	86	94.2	0.0	5.8	129.3	1.8	e
2	ABL90 FLEX / PLUS	93	98.9	0.0	1.1	129.3	0.5	e
3	ABL80 FLEX CO-OX / O	4	75.0	0.0	25.0	127.5	2.2	e*

Potassium BG



QUALAB tolerance : 6 %

Potassium BG (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas b 221	4	100.0	0.0	0.0	3.7	3.4	e*
2	Cobas b 123	19	100.0	0.0	0.0	3.7	1.2	e
3	iStat	18	100.0	0.0	0.0	3.8	1.2	e
4	EPOC	44	100.0	0.0	0.0	3.8	1.8	e
5	ABL700/800	89	100.0	0.0	0.0	3.8	1.4	e
6	ABL90 FLEX / PLUS	109	100.0	0.0	0.0	3.7	0.8	e

9 additional results were submitted but not published because the method groups were too small. (< results per group)

Sodium BG



QUALAB tolerance : 6 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas b 221	4	100.0	0.0	0.0	140.0	1.4	e*
2	Cobas b 123	19	100.0	0.0	0.0	138.3	0.5	e
3	iStat	18	100.0	0.0	0.0	142.7	0.3	e
4	EPOC	42	100.0	0.0	0.0	140.7	0.9	e
5	ABL700/800	88	100.0	0.0	0.0	140.3	0.7	e
6	ABL90 FLEX / PLUS	108	100.0	0.0	0.0	141.0	0.4	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

Chlorid-BG



QUALAB tolerance : 6 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas b 123	9	100.0	0.0	0.0	100.4	1.4	e
2	EPOC	12	100.0	0.0	0.0	100.8	1.5	e
3	ABL700/800	81	100.0	0.0	0.0	98.5	1.3	e
4	ABL90 FLEX / PLUS	102	100.0	0.0	0.0	97.0	0.5	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

Calcium-BG



MQ tolerance : 12 %
(< 2.00: +/- 0.24 mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	GEM	4	100.0	0.0	0.0	0.44	2.9	e
2	Cobas b123	13	100.0	0.0	0.0	0.38	10.6	e*
3	Roche, Cobas	7	100.0	0.0	0.0	0.46	10.8	e*
4	iStat	13	100.0	0.0	0.0	0.49	1.0	e
5	EPOC	40	97.5	0.0	2.5	0.53	3.6	e
6	ABL700/800	89	100.0	0.0	0.0	0.54	2.7	e
7	ABL90 FLEX / PLUS	105	99.0	0.0	1.0	0.53	3.3	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

FHHb



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL90 FLEX / PLUS	5	100.0	0.0	0.0	2.900	1.5	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Lactate-BG



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas b123	9	100.0	0.0	0.0	2.00	2.0	e
2	Roche, Cobas	5	100.0	0.0	0.0	1.88	3.1	e
3	IL	4	100.0	0.0	0.0	1.70	4.8	e*
4	EPOC	41	100.0	0.0	0.0	1.86	2.7	e
5	iStat	12	100.0	0.0	0.0	1.59	1.6	e
6	ABL700/800	90	100.0	0.0	0.0	1.70	3.4	e
7	ABL90 FLEX / PLUS	103	100.0	0.0	0.0	1.60	2.5	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

sO2 OR



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	iStat	16	100.0	0.0	0.0	98.688	0.5	e
2	ABL700/800	76	100.0	0.0	0.0	96.837	0.2	e
3	ABL90 FLEX / PLUS	90	100.0	0.0	0.0	96.830	0.6	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

FO2Hb OR



MQ tolerance : 20 %

FO2Hb OR (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	72	100.0	0.0	0.0	92.256	0.2	e
2	ABL90 FLEX / PLUS	91	100.0	0.0	0.0	92.137	0.1	e
3	ABL80 FLEX CO-OX / O	4	100.0	0.0	0.0	92.150	5.2	e*

FCOHb OR



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	75	92.0	5.3	2.7	2.736	10.1	e
2	ABL90 FLEX / PLUS	90	98.9	1.1	0.0	2.872	6.8	e
3	ABL80 FLEX CO-OX / O	4	75.0	25.0	0.0	2.750	18.7	e*

FMetHb OR



MQ tolerance : 20 %

FMetHb OR (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	75	96.0	1.3	2.7	1.985	5.1	e
2	ABL90 FLEX / PLUS	90	96.7	2.2	1.1	2.038	5.6	e
3	ABL80 FLEX CO-OX / O	4	100.0	0.0	0.0	2.050	4.7	e

FHbF OR



MQ tolerance : 20 %

FHbF OR (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL90 FLEX / PLUS	35	97.1	0.0	2.9	77.824	3.1	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Bilirubin OR



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	4	75.0	0.0	25.0	296.0	0.4	e
2	ABL90 FLEX / PLUS	32	93.7	0.0	6.3	298.3	0.6	e

Troponin I



QUALAB tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Pathfast	13	84.6	15.4	0.0	11477.7	16.3	e*
2	Vidas	12	91.7	8.3	0.0	14221.5	9.7	e
3	Architect High Sensi	10	100.0	0.0	0.0	3655.2	7.3	e

9 additional results were submitted but not published because the method groups were too small. (< results per group)

Troponin T



QUALAB tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas hs	10	100.0	0.0	0.0	4252.20	7.0	e
2	Cobas hs STAT	11	100.0	0.0	0.0	4268.91	5.4	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Myoglobin



QUALAB tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	8	100.0	0.0	0.0	192.0	3.8	e
2	Abbott	5	100.0	0.0	0.0	230.2	6.3	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

CK-MB mass



MQ tolerance : 40 %

CK-MB mass (µg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	9	100.0	0.0	0.0	40.8	6.6	e

9 additional results were submitted but not published because the method groups were too small. (< results per group)

BNP



QUALAB tolerance : 27 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	5	100.0	0.0	0.0	1175.5	4.6	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

NT-proBNP



QUALAB tolerance : 27 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Pathfast	10	90.0	0.0	10.0	8352.1	13.3	e*
2	VIDAS	10	100.0	0.0	0.0	2387.7	5.8	e
3	Other methods	4	100.0	0.0	0.0	4199.0	15.2	a
4	Cobas E / Elecsys	19	100.0	0.0	0.0	2859.5	5.6	e
5	Abbott	8	100.0	0.0	0.0	3364.2	6.5	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

TSH



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	25	100.0	0.0	0.0	20.31	3.6	e
2	Abbott	11	100.0	0.0	0.0	15.13	5.2	e
3	VIDAS	15	100.0	0.0	0.0	22.10	7.8	e
4	Dimension	4	100.0	0.0	0.0	19.37	4.8	e*
5	AFIAS	24	91.7	8.3	0.0	28.73	7.9	e
6	Other methods	5	80.0	0.0	20.0	19.97	10.3	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

T3



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	AFIAS	5	80.0	20.0	0.0	2.4	13.8	e*
2	Abbott	4	100.0	0.0	0.0	3.4	1.6	e

T4



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	AFIAS	5	100.0	0.0	0.0	229	11.7	e*
2	Abbott	4	100.0	0.0	0.0	169	3.7	e

FT3



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	21	100.0	0.0	0.0	15.1	2.6	e
2	Abbott	10	100.0	0.0	0.0	12.7	4.6	e
3	VIDAS	7	100.0	0.0	0.0	13.9	8.6	e*

6 additional results were submitted but not published because the method groups were too small. (< results per group)

FT4



QUALAB tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	21	100.0	0.0	0.0	48.3	3.8	e
2	Abbott	11	100.0	0.0	0.0	36.7	9.2	e*
3	VIDAS	8	100.0	0.0	0.0	51.5	4.6	e
4	Other methods	8	87.5	0.0	12.5	48.6	4.4	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Testosterone



QUALAB tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	10	100.0	0.0	0.0	21.5	4.3	e
2	ADVIA Centaur XP/CP	4	100.0	0.0	0.0	22.9	7.8	e*

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Estradiol



QUALAB tolerance : 30 %

Estradiol (pmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	9	100.0	0.0	0.0	1927	2.9	e
2	ADVIA Centaur XP/CP	4	100.0	0.0	0.0	3122	7.7	e*
3	Abbott	6	100.0	0.0	0.0	1698	5.7	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

SHBG



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	13	100.0	0.0	0.0	33.4	2.4	e
2	Abbott	5	100.0	0.0	0.0	35.6	10.9	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Cortisol



QUALAB tolerance : 20 %

Cortisol (nmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	17	100.0	0.0	0.0	735	3.6	e
2	Abbott	5	100.0	0.0	0.0	659	3.8	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Progesteron



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	6	100.0	0.0	0.0	58.1	2.8	e
2	Other methods	5	80.0	20.0	0.0	51.3	19.9	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

DHEAS



MQ tolerance : 30 %

DHEAS (µmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	10	100.0	0.0	0.0	12.11	6.9	e
2	Abbott	4	100.0	0.0	0.0	11.38	4.2	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Luteinizing hormone



QUALAB tolerance : 24 %

Luteinizing hormone (U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	9	100.0	0.0	0.0	48.1	3.7	e
2	ADVIA Centaur XP/CP	4	100.0	0.0	0.0	43.8	9.1	e*
3	Abbott	6	100.0	0.0	0.0	33.5	5.2	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Follicle-stimulating hormone



QUALAB tolerance : 24 %

Follicle-stimulating hormone (U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	9	100.0	0.0	0.0	29.0	3.0	e
2	ADVIA Centaur XP/CP	4	100.0	0.0	0.0	29.3	7.1	e*
3	Architect	7	100.0	0.0	0.0	29.3	4.4	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Prolactine



QUALAB tolerance : 24 %

Prolactine (µg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas/Roche	11	100.0	0.0	0.0	40.9	3.8	e
2	Abbott	5	100.0	0.0	0.0	33.9	4.5	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Insulin



MQ tolerance : 25 %

Insulin (pmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	11	100.0	0.0	0.0	864	7.6	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

HGH



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	6	100.0	0.0	0.0	17.96	6.9	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Freies Testosteron



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	5	80.0	20.0	0.0	56.4	14.4	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

IGF-1



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Liaison	6	100.0	0.0	0.0	111	10.7	e*
2	Other methods	4	100.0	0.0	0.0	73	11.5	e*

Troponin T CR



QUALAB tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas h 232	1323	95.5	3.1	1.4	258.06	11.0	e

D-dimer CR



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas h 232	1303	85.9	10.0	4.1	0.94	12.7	e
2	Lumira Dx	9	77.8	0.0	22.2	0.93	11.0	e*

CKMB- K8



MQ tolerance : 40 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas h 232	10	100.0	0.0	0.0	24.2	11.3	e

NT-proBNP CR



QUALAB tolerance : 27 %

NT-proBNP CR (ng/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas h 232	831	93.9	5.5	0.6	297	13.7	e

PCO2 CCA



QUALAB tolerance : 12 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OPTI CCA	12	91.7	8.3	0.0	9.37	6.4	e*

PO2 CCA



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OPTI CCA	12	91.7	0.0	8.3	9.78	6.1	e

pH CCA



QUALAB tolerance : 1 %

pH CCA ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OPTI CCA	11	100.0	0.0	0.0	7.14	0.2	e

Potassium CCA



QUALAB tolerance : 6 %
(< 3.3: +/- 0.2 mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OPTI CCA	7	100.0	0.0	0.0	2.9	3.3	e*

Sodium CCA



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OPTI CCA	6	100.0	0.0	0.0	125.0	1.8	e

Calcium CCA



MQ tolerance : 9 %
(< 2.00: +/- 0.18 mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OPTI CCA	4	75.0	0.0	25.0	1.58	1.9	e

Ferritin



QUALAB tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Dimension	4	100.0	0.0	0.0	79.05	12.3	e*
2	Beckman	9	100.0	0.0	0.0	59.00	9.4	e*
3	Cobas E / Elecsys	21	100.0	0.0	0.0	76.22	5.9	e
4	Abbott	12	100.0	0.0	0.0	98.24	5.1	e
5	Mini Vidas	8	87.5	0.0	12.5	55.50	7.3	e
6	AFIAS	32	96.9	0.0	3.1	69.85	5.4	e
7	Eurolyser	12	100.0	0.0	0.0	50.33	4.8	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Vitamin B12



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	6	100.0	0.0	0.0	240.00	7.9	e*
2	Cobas E / Elecsys	18	94.4	5.6	0.0	238.09	8.8	e
3	Abbott	11	100.0	0.0	0.0	216.94	8.6	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Folate



QUALAB tolerance : 24 %
(< 10.00: +/- 2.40 nmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	5	100.0	0.0	0.0	7.00	8.3	e*
2	Cobas E / Elecsys	18	100.0	0.0	0.0	7.89	11.1	e
3	Abbott	10	100.0	0.0	0.0	11.70	11.1	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Holotranscobalamine



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	16	100.0	0.0	0.0	64.7	7.7	e
2	Other methods	20	95.0	5.0	0.0	54.9	9.6	e

Bilirubin total Neo



QUALAB tolerance : 18 %

Bilirubin total Neo (µmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	15	100.0	0.0	0.0	95	8.1	e
2	Dimension	4	100.0	0.0	0.0	105	1.3	e

Bilirubin direct



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	20	100.0	0.0	0.0	55	6.6	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Bilirubin neonatal



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	10	100.0	0.0	0.0	109	4.5	e
2	Other methods	12	100.0	0.0	0.0	128	2.1	e

PSA



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	19	100.0	0.0	0.0	9.11	6.0	e
2	Abbott	7	100.0	0.0	0.0	8.82	5.7	a
3	AFIAS	16	93.7	0.0	6.3	9.41	4.2	e

9 additional results were submitted but not published because the method groups were too small. (< results per group)

free PSA



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	11	100.0	0.0	0.0	3.03	4.5	e
2	Abbott	5	100.0	0.0	0.0	3.38	4.6	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

CEA



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	13	100.0	0.0	0.0	6.9	6.2	e
2	Abbott	6	100.0	0.0	0.0	10.0	4.9	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

CA 125



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	9	100.0	0.0	0.0	101.0	11.4	a

7 additional results were submitted but not published because the method groups were too small. (< results per group)

CA 19-9



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	6	100.0	0.0	0.0	17.5	6.6	e

8 additional results were submitted but not published because the method groups were too small. (< results per group)

CA 15-3



MQ tolerance : 25 %

CA 15-3 (kIU/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	11	100.0	0.0	0.0	38.8	10.4	e*
2	Abbott	4	100.0	0.0	0.0	43.6	7.8	e*

5 additional results were submitted but not published because the method groups were too small. (< results per group)

AFP



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	9	100.0	0.0	0.0	73.1	9.8	e*
2	Abbott	4	100.0	0.0	0.0	75.3	1.2	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

HCG qn



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	13	92.3	7.7	0.0	87.6	11.5	e*
2	VIDAS	9	100.0	0.0	0.0	42.6	13.1	d
3	Architect	8	100.0	0.0	0.0	76.4	5.1	e
4	AFIAS	7	100.0	0.0	0.0	147.0	6.2	e

8 additional results were submitted but not published because the method groups were too small. (< results per group)

HCG intact



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	5	100.0	0.0	0.0	33.0	2.2	e

S100



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	4	100.0	0.0	0.0	2.74	3.9	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Thyreoglobulin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	4	100.0	0.0	0.0	37.5	4.7	e
2	Other methods	4	100.0	0.0	0.0	68.1	14.1	e*

CK-MB



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Fuji Dri-Chem	26	96.2	0.0	3.8	60.4	7.4	e
2	Cobas/Roche	8	100.0	0.0	0.0	59.5	3.0	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Cholesterol PTS



QUALAB tolerance : 10 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CardioChek	16	68.7	18.8	12.5	6.48	8.0	e*

Cholesterol HDL PTS



QUALAB tolerance : 21 %

Cholesterol HDL PTS (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CardioChek	16	81.2	6.3	12.5	1.80	7.7	e

Triglycerides



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CardioChek	16	93.7	0.0	6.3	1.47	5.3	e

C-Peptid



MQ tolerance : 25 %

C-Peptid (nmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Liaison	6	100.0	0.0	0.0	3.74	7.2	e
2	Other methods	5	100.0	0.0	0.0	2.98	5.7	e

ACTH



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	7	100.0	0.0	0.0	21.00	12.7	e*
2	Liaison	4	100.0	0.0	0.0	36.15	7.0	e*

Procalcitonin



QUALAB tolerance : 27 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	6	100.0	0.0	0.0	12.58	1.8	e
2	Cobas	13	100.0	0.0	0.0	9.87	4.5	e
3	VIDAS	12	91.7	0.0	8.3	7.61	4.0	e
4	Other methods	5	100.0	0.0	0.0	9.27	13.2	e*
5	Liaison	4	75.0	0.0	25.0	15.30	7.6	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

EPO



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	4	100.0	0.0	0.0	174.8	8.8	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Parathyroid hormone



QUALAB tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas PTH STAT	12	100.0	0.0	0.0	36.8	3.8	e
2	Cobas	8	100.0	0.0	0.0	30.1	2.9	e
3	Abbott	5	100.0	0.0	0.0	68.5	4.5	e

9 additional results were submitted but not published because the method groups were too small. (< results per group)

Osmolality



QUALAB tolerance : 6 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cryoskopy	22	95.5	0.0	4.5	389	1.4	e

Potassium-K22



QUALAB tolerance : 6 %

Potassium-K22 (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ISE	12	100.0	0.0	0.0	3.8	1.6	e

Sodium-K22



QUALAB tolerance : 6 %

Sodium-K22 (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ISE	12	100.0	0.0	0.0	133	0.7	e

Glucose-K22



QUALAB tolerance : 9 %

Glucose-K22 (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	12	100.0	0.0	0.0	5.9	2.4	e

Urea-K22



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	12	100.0	0.0	0.0	4.6	4.5	e

Osmotic Gap



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Formel 1 (2Na+K+Glu+	10	100.0	0.0	0.0	110.5	6.7	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Digoxin



QUALAB tolerance : 24 %

Digoxin (nmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	9	100.0	0.0	0.0	2.20	5.2	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Phenytoin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	4	100.0	0.0	0.0	51	10.1	e*

Phenobarbital



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	4	100.0	0.0	0.0	137	3.2	e

Vancomycin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	4	100.0	0.0	0.0	13.5	7.6	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Valproat



MQ tolerance : 24 %

Valproat (µmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	8	100.0	0.0	0.0	539.5	4.8	e

Carbamazepin



MQ tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	4	100.0	0.0	0.0	38.2	7.2	e*

Cystatin C



MQ tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	14	92.9	0.0	7.1	0.73	10.2	a

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Ethanol



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Others	5	60.0	0.0	40.0	14.2	2.5	e
2	Abbott	6	100.0	0.0	0.0	14.1	8.3	e*
3	Roche, Cobas	20	100.0	0.0	0.0	14.0	5.2	e

Ammonia



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	4	100.0	0.0	0.0	63.9	10.9	e*
2	all Participants	5	100.0	0.0	0.0	84.0	2.8	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Calprotectin



MQ tolerance : 40 %
(< 50: +/- 20 µg/g)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Bühlmann ELISA	4	100.0	0.0	0.0	64	11.8	e*
2	Bühlmann fCALturbo	15	93.3	6.7	0.0	39	24.2	e*
3	Bühlmann Quantum Blu	4	75.0	0.0	25.0	32	5.6	e
4	Liaison	19	89.5	0.0	10.5	24	25.9	e*
5	Ridas Screen DS2	4	100.0	0.0	0.0	32	23.3	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Cholesterol total Af/b101



QUALAB tolerance : 10 %

Cholesterol total Af/b101 (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas b101	280	98.6	0.7	0.7	5.53	2.3	e
2	Afinion	415	99.1	0.7	0.2	5.43	3.6	e

Cholesterol HDL Af/b101



QUALAB tolerance : 21 %

Cholesterol HDL Af/b101 (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas b101	276	92.1	0.7	7.2	1.20	4.4	e
2	Afinion	413	93.2	0.0	6.8	1.09	4.5	e

Tryglycerides Af/b101



QUALAB tolerance : 18 %

Tryglycerides Af/b101 (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas b101	277	99.3	0.0	0.7	2.00	2.5	e
2	Afinion	416	99.3	0.0	0.7	1.88	4.6	e

Troponin I S



QUALAB tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	AFIAS	217	86.7	5.5	7.8	1132.31	11.1	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

D-dimer qn S



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	AFIAS	223	85.2	1.3	13.5	0.88	9.7	e

NT-proBNP S



QUALAB tolerance : 27 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	AFIAS	171	81.9	0.6	17.5	7640.1	8.9	e

Homocystein



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	4	100.0	0.0	0.0	11.3	16.5	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Lipase



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	12	100.0	0.0	0.0	94.7	5.0	e
2	Beckman	5	100.0	0.0	0.0	97.0	0.8	e
3	Cobas	24	100.0	0.0	0.0	104.2	5.5	e
4	Fuji Dri-Chem	180	96.7	0.0	3.3	92.6	4.2	e

9 additional results were submitted but not published because the method groups were too small. (< results per group)

Bicarbonat



MQ tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	4	100.0	0.0	0.0	22.6	2.3	e
2	Other methods	4	100.0	0.0	0.0	18.9	7.1	e*

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Glucose CSF



QUALAB tolerance : 9 %
(< 3.30: +/- 0.30 mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	9	100.0	0.0	0.0	2.23	2.4	e
2	Other methods	12	100.0	0.0	0.0	2.21	3.6	e

Lactate CSF



QUALAB tolerance : 18 %

Lactate CSF (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	7	100.0	0.0	0.0	3.10	3.1	e
2	Other methods	10	90.0	0.0	10.0	3.07	4.6	e

Protein CSF



QUALAB tolerance : 15 %

Protein CSF (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	8	100.0	0.0	0.0	0.71	3.4	e
2	Other methods	10	100.0	0.0	0.0	0.71	6.2	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Albumine CSF



MQ tolerance : 20 %

Albumine CSF (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	4	100.0	0.0	0.0	298.50	3.0	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

CDT



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	7	85.7	14.3	0.0	1.00	9.8	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Tacrolimus



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	9	100.0	0.0	0.0	15.6	5.1	e

Totalprotein E



MQ tolerance : 12 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	17	100.0	0.0	0.0	78.7	2.7	e

Albumin E



MQ tolerance : 12 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	25	96.0	4.0	0.0	60.9	7.7	e*

alpha-1-Globuline



MQ tolerance : 30 %

alpha-1-Globuline (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	9	100.0	0.0	0.0	2.2	4.9	e
2	capillary electropho	16	100.0	0.0	0.0	3.7	13.0	e

alpha-2-Globuline



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	25	96.0	4.0	0.0	8.5	8.8	e

beta-Globuline



MQ tolerance : 30 %

beta-Globuline (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	14	100.0	0.0	0.0	9.7	11.4	e

Beta-1-Globulin



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	13	100.0	0.0	0.0	7.6	10.4	e

Beta-2-Globulin



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	9	100.0	0.0	0.0	3.8	6.5	e

gamma-Globuline



MQ tolerance : 30 %

gamma-Globuline (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	17	94.1	0.0	5.9	18.3	7.3	e

Gamma-Globuline+P



MQ tolerance : 30 %

Gamma-Globuline+P (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	8	100.0	0.0	0.0	14.7	2.9	e

Immunfixation



QUALAB tolerance : 1 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Interpretation	23	100.0	0.0	0.0	8	0.0	e

Folate in Erythrocytes



MQ tolerance : 40 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Alinity	7	100.0	0.0	0.0	150	10.5	e
2	Abbott	5	100.0	0.0	0.0	192	8.1	e
3	Roche, Cobas	14	100.0	0.0	0.0	1181	12.2	e
4	ADVIA Centaur XP/CP	5	80.0	0.0	20.0	499	11.6	a

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Gallensäure



MQ tolerance : 30 %
(< 5.0: +/- 1.5 µmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	10	100.0	0.0	0.0	6.2	19.6	a
2	all Participants	16	100.0	0.0	0.0	3.6	15.5	e*

BNP



QUALAB tolerance : 27 %
(< 75.0: +/- 20.0 ng/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Triage	11	100.0	0.0	0.0	10.9	22.2	e*

Troponin Triage



QUALAB tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Triage high sensitiv	53	88.6	5.7	5.7	406.00	12.2	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

NT-pro BNP



QUALAB tolerance : 27 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Triage	34	85.3	11.8	2.9	229	13.6	e

D-dimer Triage



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Triage	61	83.6	13.1	3.3	1149.37	14.2	e

Vitamin D 25 (OH)



QUALAB tolerance : 27 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	LCMS	5	100.0	0.0	0.0	47.2	7.6	e*
2	Cobas	14	100.0	0.0	0.0	52.4	12.4	e*
3	VIDAS	6	100.0	0.0	0.0	49.9	7.9	e*
4	Other methods	17	70.6	11.8	17.6	55.8	19.1	e*
5	Architect	10	100.0	0.0	0.0	50.0	9.6	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

AMH



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	15	100.0	0.0	0.0	20.9	6.1	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Inhibin B



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	5	100.0	0.0	0.0	238.7	14.3	e*

Calcitonin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Liaison	5	100.0	0.0	0.0	4.4	0.3	e
2	Other methods	5	100.0	0.0	0.0	14.1	6.1	e

IGF-BP3



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	4	100.0	0.0	0.0	3.76	11.3	a

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Renin



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Liaison	4	100.0	0.0	0.0	68.9	2.6	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Aldosteron



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	4	100.0	0.0	0.0	39	12.1	e*

Anti Thyreoglobulin



MQ tolerance : 25 %

Anti Thyreoglobulin (IU/ml)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Alinity	4	100.0	0.0	0.0	136	1.4	e
2	Cobas	9	100.0	0.0	0.0	842	14.9	a

9 additional results were submitted but not published because the method groups were too small. (< results per group)

Anti TPO



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Alinity	4	100.0	0.0	0.0	97	3.3	e
2	Cobas	10	90.0	10.0	0.0	165	14.5	e*

8 additional results were submitted but not published because the method groups were too small. (< results per group)

TRAK



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	6	100.0	0.0	0.0	4.52	10.2	e*
2	Roche, Cobas	6	100.0	0.0	0.0	2.75	11.4	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Creatinine WB



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Statsensor i / Nova	59	61.1	20.3	18.6	105	14.6	e

IL6



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	6	100.0	0.0	0.0	1417.0	3.1	e

Pankreas Elastase



MQ tolerance : 0 %

Pankreas Elastase (ug/g)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Liaison	6	100.0	0.0	0.0	4	45.5	a

Calcium-Urine



MQ tolerance : 9 %
(< 2.00: +/- 0.18 mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	13	100.0	0.0	0.0	2.08	2.1	e
2	Abbott	9	100.0	0.0	0.0	1.97	0.9	e
3	Other methods	4	100.0	0.0	0.0	2.11	2.7	e*

Chloride-Urine



MQ tolerance : 12 %

Chloride-Urine (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	10	100.0	0.0	0.0	154	0.9	e
2	Roche, Cobas	12	100.0	0.0	0.0	147	2.7	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Glucose-Urine



QUALAB tolerance : 9 %

Glucose-Urine (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	20	100.0	0.0	0.0	9.1	2.2	e

Magnesium-Urine



MQ tolerance : 12 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	14	100.0	0.0	0.0	2.70	5.6	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Osmolality-Urine



MQ tolerance : 10 %

Osmolality-Urine (mosm/kg)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cryoskopy	19	100.0	0.0	0.0	630	0.8	e

Phosphate-Urine



MQ tolerance : 15 %

Phosphate-Urine (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	23	100.0	0.0	0.0	12.2	3.5	e

Potassium-Urine



MQ tolerance : 15 %

Potassium-Urine (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	32	100.0	0.0	0.0	51	2.6	e

Protein-Urine



QUALAB tolerance : 20 %

Protein-Urine (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas/Roche	17	94.1	0.0	5.9	350.6	4.2	e
2	Standard chemistry	15	100.0	0.0	0.0	436.3	4.4	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Sodium-Urine



MQ tolerance : 15 %

Sodium-Urine (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	33	100.0	0.0	0.0	129	1.7	e

Urea-Urine



MQ tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	29	100.0	0.0	0.0	205	5.0	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Uric Acid-Urine



MQ tolerance : 15 %

Uric Acid-Urine (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	19	100.0	0.0	0.0	1.03	3.1	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Specific Gravity-Urine



MQ tolerance : 5 %

Specific Gravity-Urine ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Refractometer	7	100.0	0.0	0.0	1.018	0.1	e

Ethylglucuronid



MQ tolerance : 25 %

Ethylglucuronid (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	4	100.0	0.0	0.0	2.82	21.9	a

Creatinine U



QUALAB tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	12	100.0	0.0	0.0	72.8	2.3	e
2	Roche, Cobas	13	100.0	0.0	0.0	64.2	4.6	e
3	Aution	4	50.0	0.0	50.0	80.0	0.0	a
4	AFIAS	15	93.3	0.0	6.7	76.7	10.4	e
5	Afinion	467	95.9	2.6	1.5	68.6	10.2	e
6	Sysmex U	19	78.9	0.0	21.1	80.0	0.0	e
7	Other methods	5	20.0	0.0	80.0	80.0	0.0	a
8	Turbidimetry	6	100.0	0.0	0.0	70.8	10.6	e*
9	DCA2000/Vantage	157	95.0	2.5	2.5	68.5	9.1	e
10	Siemens Clinitek	17	64.7	0.0	35.3	80.0	0.0	a

Creatinin Urin



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	DCA2000/Vantage	153	90.9	1.3	7.8	5.5	6.9	e
2	Siemens Clinitek	9	55.6	0.0	44.4	4.4	0.2	a
3	Afinion	463	98.1	0.6	1.3	4.9	5.5	e
4	Standard chemistry	45	100.0	0.0	0.0	5.1	5.4	e
5	Sysmex U	15	86.7	0.0	13.3	4.4	0.1	a
6	Aution	4	75.0	0.0	25.0	4.4	0.0	a
7	Siemens Clinitek	8	12.5	0.0	87.5	4.4	0.0	a
8	Other methods	5	100.0	0.0	0.0	4.4	0.2	a

2 additional results were submitted but not published because the method groups were too small. (< results per group)